Go Back Imatinib Mesylate
Product Detail
| Cat # | PKI-IMTB-050 |
| Size | 50 mg |
| Price |
$1,200.00 |
Imatinib, formerly referred to as STI571, is a specific ATP competitive inhibitor of Bcr-Abl tyrosine kinase (IC50 = 0.25 �M) and at present the first-choice treatment for patients with chronic myeloid leukaemia (CML). However, some patients show resistance to imatinib either due to point mutations in the Abl kinase domain or because of genomic amplification of bcr-abl. Other therapeutic targets for imatinib mesylate are c-KIT or platelet-derived growth factor receptor (PDGFR) that are expressed constitutively in gastrointestinal stromal tumors (GISTs), whereas inhibitory activity against other kinases (EGFR, INS-R, IGF-R and JAK2) is at least 100-fold lower.